Histological evidence of World Health Organization (WHO) grade III anaplastic glioma or WHO grade II low grade glioma with locally diagnosed combined p/q loss and the presence of an either IDH or IDH, both as established by a local or referenced laboratory qualified for the study\r\n* Note: mixed gliomas are eligible, regardless of the degree of astrocytic or oligodendrocytic predominance, as long as the tumor is also co-deleted for p and q
Patients with low grade glioma patients (World Health Organization [WHO] grades I and II) are not eligible
Have histologically confirmed World Health Organization (WHO) grade II or III meningioma that is progressive or recurrent; metastatic meningiomas are allowed; participants must have failed maximal safe resection and radiation therapy
Patients must have histologically confirmed diagnosis of glioblastoma multiforme (GBM) or anaplastic glioma, World Health Organization (WHO) grade  or 
Patients must have refractory, progressive or recurrent confirmed low-grade glioma (World Health Organization [WHO] grade I or II) that was confirmed histologically at initial diagnosis
Patients must have a newly diagnosed or recurrent World Health Organization (WHO) grade II astrocytoma, oligoastrocytoma or oligodendroglioma that has been histologically confirmed by prior biopsy or surgical resection; if the pathological diagnosis was made outside of University of California San Francisco (UCSF), the pathology must be reviewed and confirmed at UCSF
Histologically confirmed atypical meningioma, World Health Organization (WHO) grade II, Simpson grade - that has been either subtotally resected or biopsied; OR
Pathological criteria - patients must have a newly diagnosed or recurrent World Health Organization (WHO) grade II glioma (defined as an astrocytoma, oligodendroglioma, or oligoastrocytoma) that is to be histologically confirmed by clinically indicated resection; if patients have already undergone biopsy and have pathologic diagnosis of WHO grade II glioma, pathology must be reviewed and confirmed at University of California San Francisco (UCSF)
Patients must have a clinical and histopathologic diagnosis of diffuse astrocytoma (World Health Organization, WHO, grade II, III or IV astrocytoma), have completed > % of prescribed concurrent radiation therapy and adjuvant temozolomide without Common Terminology Criteria for Adverse Events (CTCAE) grade  leukopenia, neutropenia, or thrombocytopenia, and be greater than  months from the time of completion of concurrent chemoradiotherapy, with stable disease by neuroimaging
Patients with pathology confirmed newly diagnosed World Health Organization (WHO) grade IV glioma
Have a histologically proven well-differentiated neuroendocrine tumor (World Health Organization [WHO] grade , grade , or morphologically and/or clinically well-differentiated grade )
Histologically confirmed diagnosis of World Health Organization grade IV malignant glioma
First disease progression or disease recurrence (>=  cm and =<  cm) of a partially or completely resectable, supratentorial World Health Organization (WHO) grade IV malignant glioma (GBM or gliosarcoma) based on imaging studies with measurable disease
Diagnosis of recurrent or progressive histologically confirmed World Health Organization (WHO) grade I-III meningioma which has failed maximal safe resection and radiation therapy
Histologically confirmed diagnosis of malignant glioma by enrolling institution:\r\n* World Health Organization (WHO) grade IV tumors (glioblastoma [GBM] or its variants)\r\n* WHO grade III anaplastic astrocytoma or oligodendroglial tumors or\r\n* WHO grade II gliomas, if magnetic resonance imaging (MRI) shows contrast enhancement
Patients must have a recurrent supratentorial WHO grade IV malignant glioma based on imaging studies with measurable disease (>=  cm and =< . cm of contrast-enhancing tumor); prior histopathology consistent with a World Health Organization (WHO) grade IV malignant glioma confirmed by the study pathologist, Roger McLendon, or his designate
Patients with relapsed or refractory high grade glioma (HGG) defined was histologically confirmed World Health Organization (WHO) grade III or WHO grade IV glioma (i.e. glioblastoma multiforme or anaplastic astrocytoma); patients must have had histologic verification of malignancy at original diagnosis or relapse; metastatic disease to the spine is eligible; patients may be in first, second, or third relapse; subjects with intrinsic brain stem gliomas may be eligible if histologically confirmed; please contact study chair prior to enrollment
Patients must have a prior diagnosis of grade IV glioma (glioblastoma) per  World Health Organization (WHO) criteria, that has progressed after standard radiotherapy (RT) and temozolomide (TMZ) (Note: Pathology will need to be reviewed locally but registration can occur based on pathology report)
Pathologically documented, and definitively diagnosed recurrent World Health Organization (WHO) Grade IV astrocytoma (GBM).
Patients must have histologically confirmed initial diagnosis of primary intracranial World Health Organization (WHO) Grade IV malignant glioma (glioblastoma, GBM), now recurrent. Patients with recurrent disease whose initial diagnostic pathology confirmed glioblastoma will not need re-biopsy. Alternately, patients with prior intracranial low-grade glioma or anaplastic glioma will be eligible, if histologic assessment demonstrates transformation to GBM (first diagnosis of secondary GBM).
Subjects must have histologically or cytologically confirmed World Health Organization (WHO) grade  glioma for which a clinically indicated tumor resection is planned
Subjects must have histologically confirmed diagnosis of World Health Organization (WHO) grade III or IV malignant glioma
Patients must have histologically confirmed diagnosis of World Health Organization (WHO) grade  malignant glioma and radiographic evidence of recurrence or disease progression (as defined by the Response Assessment in Neuro-Oncology [RANO] criteria as a greater than % increase in the largest bi-dimensional product of enhancement or a new enhancing lesion, or a significant increase in T-weighted-Fluid-Attenuated Inversion Recovery [T/FLAIR] abnormality without another co-morbid cause)
Participants must have either:\r\n* Histologically confirmed low-grade gliomas as defined by, World Health Organization (WHO) classification I-II/IV; these tumors can include astrocytomas, oligodendrogliomas, and mixed variants such as oligoastrocytomas; WHO classification is not required when pathology can only confirm that glioma is low grade; Karnofsky performance status (KPS) must be >=  OR\r\n* Histologically confirmed favorable anaplastic glioma as defined by WHO grade III with either or both isocitrate dehydrogenase  (IDH) mutation or p/q codeletion; in addition, these participants must have a KPS >= 
Histologically proven, newly diagnosed World Health Organization (WHO) grade III or IV astrocytoma that has a methylated MGMT promoter as assessed by the standardized institutional analysis
The subject must have histological confirmation of GBM (World Health Organization [WHO] grade IV)
Histologically confirmed diagnosis of World Health Organization grade III or IV malignant glioma
Newly diagnosed and histologically confirmed supratentorial World Health Organization (WHO) Grade IV astrocytoma status-post maximally achievable resection
Histologically confirmed diagnosis of World Health Organization (WHO) grade III (except anaplastic oligodendroglioma) or IV malignant glioma
Newly diagnosed and recurrent high grade gliomas (World Health Organization [WHO] grades III & IV) and high risk WHO grade II gliomas who are to begin treatment with monthly high dose temozolomide therapy
Diagnosis of histologically confirmed GBM (World Health Organization [WHO] grade IV)
Patients must have histologically confirmed newly diagnosed high-grade glioma (World Health Organization [WHO] grade III or IV)
Patients must have a recurrent supratentorial WHO grade IV malignant glioma based on imaging studies with measurable disease (>=  cm and =< . cm of contrast-enhancing tumor); prior histopathology consistent with a World Health Organization (WHO) grade IV malignant glioma confirmed by the study pathologist, Roger McLendon, or his designate
Patients must have histologically confirmed diagnosis of glioblastoma multiforme (GBM) or anaplastic glioma, World Health Organization (WHO) grade  or 
The patient must have a histopathologic diagnosis of a World Health Organization (WHO) grade IV GBM as confirmed by the study pathologist, Roger McLendon, or his designate; the patient must undergo leukapheresis after definitive resection; residual radiographic contrast enhancement on post-resection computed tomography (CT) or magnetic resonance imaging (MRI) must not exceed  cm in diameter in two perpendicular axial planes; patients with evidence of contrast-enhancement exceeding  cm in diameter in two perpendicular axial planes after radiation will not be a candidate for the vaccine despite being previously enrolled and will be removed from the study and replaced; those that have transformed to a grade IV GBM from a lower grade glioma will be eligible so long as they are treatment nave other than steroids, radiation therapy (RT), or TMZ
Frozen section diagnosis of World Health Organization (WHO) grade IV glioma, confirmed with permanent section and immunopositive for IGF-R
Histologically or cytologically confirmed well differentiated low or intermediate grade (World Health Organization [WHO] Grade  or ) NET of pancreatic, gastrointestinal, lung, or undetermined origin that is locally advanced or metastatic and has progressed within the past  months
Histologically proven diagnosis of supratentorial, World Health Organization (WHO) grade II or III astrocytoma, oligodendroglioma or oligoastrocytoma, with IDH mutation confirmed by central review
Patient with diagnosis of glioma, or other World Health Organization (WHO) grade II - IV primary brain tumor
Patients must have histologically confirmed World Health Organization (WHO) grade  or  gliomas
Patients must have histologically confirmed high grade glioma by pathology (World Health Organization [WHO] grade III and IV)
Patients with newly diagnosed World Health Organization (WHO) grade III or IV astrocytoma who will undergo concomitant radiation and temozolomide followed by adjuvant temozolomide
Tumor pathology: suspected or confirmed newly diagnosed or recurrent malignant gliomas World Health Organization (WHO) grade IV
Pathologic evidence (either diagnostic pathology slides or pathology report) of a diagnosis of World Health Organization (WHO) grade II or III glioma prior to treatment with temozolomide or PCV chemotherapy
